Heron Therapeutics is trading 33.11% up now at $0.39 after announcing a definitive agreement to sell substantially all assets to CorMedix. - The deal includes $145 million cash, CorMedix shares and potential additional payments; it is subject to stockholder approval and other closing conditions. - Third-quarter revenue was $35.3 million, down from $38.2 million a year earlier; 2026 guidance remains withdrawn.